ALB and hepatocellular carcinoma: From a practical perspective, these odds ratios can permit a clinician to calculate the odds of achieving a successful bridging or downstaging to LT criteria in patients undergoing Y90-RE therapy for HCC, by applying the odds ratio either in a single fashion whenever a covariable prognosticator is present (e.g., left lobe HCC disease) or in multiplicative fashion whenever a continuous numerical prognosticator is present (e.g., serum albumin level).